Lunai Bioworks unit bankrupt, to book impairment

Lunai Bioworks, Inc. reported that the Court of Amsterdam declared its indirect subsidiary Gedi Cube B.V. bankrupt on September 2, 2025, following Gedi’s voluntary petition after it could no longer meet its payment obligations.

Rhea-AI Filing Summary

Lunai Bioworks, Inc. reported that the Court of Amsterdam declared its indirect subsidiary Gedi Cube B.V. bankrupt on September 2, 2025, following Gedi’s voluntary petition after it could no longer meet its payment obligations. A court-appointed receiver will oversee the bankruptcy process. Lunai is evaluating how this development may affect its supply chain, customer relationships, and projects that had relied on Gedi, and management is putting contingency plans in place to limit operational disruption.

In connection with this bankruptcy, Lunai’s management concluded that a material impairment of assets has occurred and expects to record an impairment charge in the quarter ending September 30, 2025. The company plans to disclose the impairment in its upcoming Form 10-Q or earlier if available. Lunai emphasized that neither the parent company nor any other subsidiaries are seeking bankruptcy protection and that their operations will continue as usual.

Positive

• None.

Negative

• Bankruptcy of key subsidiary: Gedi Cube B.V., an indirect subsidiary, has been declared bankrupt after failing to meet obligations, creating operational and strategic uncertainty around its former activities.
• Material asset impairment: Management has concluded that a material impairment will be recorded for the quarter ending September 30, 2025, signaling a meaningful negative financial impact.

Insights

Credit & event-risk analyst

Subsidiary bankruptcy triggers material impairment but core operations continue.

The bankruptcy of Gedi Cube B.V., an indirect subsidiary of Lunai Bioworks, reflects financial distress at a non-core entity that could still impact operations tied to Gedi’s role in the supply chain, customer relationships, and supported projects. A court-appointed receiver in Amsterdam will manage Gedi’s bankruptcy, which typically limits Lunai’s direct control over those assets.

Management has already determined that the event causes a material asset impairment, to be recognized in the quarter ending September 30, 2025. The lack of quantified impact in this disclosure means investors must wait for the Form 10-Q or an earlier update for exact figures and any related cash effects. Lunai’s statement that neither the parent nor other subsidiaries are entering bankruptcy and will continue operating as usual helps frame this as a contained, though financially meaningful, event at the subsidiary level.

8-K Event Classification

2 items: 2.06, 8.01

2 items

Item 2.06 Material Impairments Financial

The company concluded that a material charge for impairment of assets (goodwill, intangibles, etc.) is required.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lunai Bioworks (RENB) disclose about Gedi Cube B.V.?

Lunai Bioworks disclosed that on September 2, 2025, the Court of Amsterdam declared its indirect subsidiary Gedi Cube B.V. bankrupt after Gedi filed a voluntary petition due to its inability to make payments as they became due.

Does the bankruptcy of Gedi Cube B.V. affect Lunai Bioworks’ other operations?

Lunai Bioworks stated that neither the parent company nor its other subsidiaries are filing for bankruptcy protection and that they will continue to operate their businesses as usual, while monitoring impacts on supply chain, customers, and projects.

Will Lunai Bioworks (RENB) record an impairment because of the Gedi bankruptcy?

Yes. Management determined that a material impairment of assets has occurred in connection with Gedi’s bankruptcy and expects to record an impairment charge for the quarter ending September 30, 2025.

When will Lunai Bioworks report the impairment charge related to Gedi Cube B.V.?

Lunai Bioworks expects to report the impairment charge in its Form 10-Q for the quarter ended September 30, 2025, or sooner if the information becomes available.

Who is overseeing the bankruptcy of Gedi Cube B.V.?

The Court of Amsterdam appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy of Gedi Cube B.V., and he will oversee the bankruptcy process.

How is Lunai Bioworks responding operationally to Gedi Cube B.V.’s bankruptcy?

Lunai Bioworks indicated that it is monitoring potential impacts on its supply chain, customer relationships, and projects formerly supported by Gedi, and that management is implementing contingency plans to mitigate business disruption.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/05/2025 - 05:12 PM Learn about SEC filing dates

false 0001527728 0001527728 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities ExchangeAct of 1934

Date of Report (Date of earliest event reported): September 2, 2025

LUNAI BIOWORKS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38751		45-2259340
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

2080 Century Park East, Suite 906

Los Angeles, CA 90067

(Address of principal executive offices)

+1 (305) 918-1980

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of theAct:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share	RENB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 2, 2025, the Court of Amsterdam (the “Court”) declared bankrupt Gedi Cube B.V. (“Gedi”), an indirect subsidiary of Lunai Bioworks, Inc. (“Lunai”), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking a declaration of bankruptcy due to its inability to make payments as they became due. The Company is monitoring potential impacts on its supply chain, customer relationships, and ongoing projects that were previously supported by Gedi. Management is implementing contingency plans to mitigate any business disruption. Neither Lunai nor any of its other subsidiaries are filing for bankruptcy protection, and Lunai and its other subsidiaries will continue to operate their businesses as usual.

Item 2.06 – Material Impairments

In connection with the bankruptcy described in Item 8.01, management determined on September 2, 2025 that a material impairment of assets has occurred. The Company expects to record an impairment charge for the quarter ending September 30, 2025, however, is unable to make a good faith estimate of the same or the cash expenditures resulting from the impairment charge, if any, at the time of this filing. The Company expects to report the impairment charge in its quarterly report on Form 10-Q for the quarter ended September 30, 2025 or sooner if available.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LUNAI BIOWORKS, INC.
	By:	/s/ David Weinstein
	Name:	David Weinstein
	Title:	Chief Executive Officer

Date:September 5, 2025